AnaCardio

Stockholm, Sweden · Founded 2017 · Privately Held (backing)

Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. AnaCardio is based in Stockholm, Sweden and was founded in 2017. It was valued at $293 million at its Series B in Sep 2026, the last priced event on record. It has raised $44.2 million across 1 recorded round; the latest was a Series B in Sep 2026.

PMV mark · valuation
$292.9M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$44.2M
Last round
Series B
Sep 2026

Who backs AnaCardio?

13 investors
InvestorType
Novo HoldingsOther
InnovestorVenture capital
IndustrifondenVenture capital
Nordic Mentor Network For EntrepreneurshipOther
Helsinn HealthcareOther
3B Future Health Fund—
EIC Scaling Club—
Flerie—
Fredrik and Ann-Helene Ljungström—
Karolinska Development—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

AnaCardio investors

13 investors are on record for AnaCardio, including Novo Holdings, Innovestor, Industrifonden and Nordic Mentor Network For Entrepreneurship. The Series B in Sep 2026 drew 9 investors.

Free account
More of AnaCardio with a free account
  • ·The post-money valuation on its round
  • ·The complete investor list: 13 names
  • ·Watch AnaCardio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like AnaCardio. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View